The Developmental Therapeutics Program (DTP) of the NCI is seeking candidates with an advanced degree in Toxicology, Pharmacology or equivalent for the position of Branch Chief, Toxicology and Pharmacology Branch (TPB).
The candidate will be a Supervisory Toxicologist directing the activities of the TPB (https://dtp.cancer.gov/organization/tpb/) and will collaborate with investigators of the NCI DTP (https://dtp.cancer.gov/). The candidate will manage and coordinate all functional requirements for the branch including formulation of research and/or testing the biological, toxicological, and carcinogenic potential of chemicals, and/or biopharmaceutical agents and make recommendations for the development of new or revised programs to meet existing needs in the areas of toxicology, pharmacology and pharmacodynamics.
The candidate initiates and develops research projects investigating mechanisms underlying the toxicity of chemicals, classes of chemicals, or other agents or other important topics related to cancer therapeutics research. Candidates with interest in developing model systems for predicting and measuring toxicological and pharmacological properties of anticancer agents are of particular interest.
This is an exploratory ad to gauge interest and a possible candidate pool. A vacancy Announcement (VA) to fill the position will be posted on WWW.USAJOBS.GOV at a later date.
Candidates must be U.S. citizens. Compensation for this position is commensurate with the individual’s qualifications and experience as permitted within Federal Government appointments.
Please submit your C.V., a statement of interest and contact information for three references to Dr. Rosemarie Aurigemma, Developmental Therapeutics Program, National Cancer Institute at firstname.lastname@example.org (phone 240-276-5465).
DHHS, NIH and NCI are Equal Opportunity Employers.
Internal Number: TPBBC1
About National Cancer Institute, DCTD, DTP
The NCI Development Therapeutics Program (DTP) provides services and resources to the academic and private-sector research communities worldwide to facilitate the discovery and development of new cancer therapeutic agents. Since its inception in 1955 by Congress, DTP has supported the development of more than 40 US-licensed anti-cancer agents through extensive collaborations with academic, pharmaceutical and biotechnology industries, including Paclitaxel, Romidepsin, Eribulin, Sipuleucel-T, and Dinutuximab (Ch14.18).Today, most of DTP’s drug discovery and development services are available for academic and private researchers through applying for NCI Experimental Therapeutic program (NExT). Under this new framework, DTP continues to help academic and private sectors to overcome financial and technical barriers, particularly through supporting high-risk treatments for rare cancers, and facilitate the movement of promising therapeutic agents from scientists’ bench side to patients’ bed side.